TW001

Drug Name: TW001
Company: Treeway
Location: Netherlands
Website: http://www.treeway.nl/
Drug Type: Small Molecule
Conditions: ALS
Mechanism Type: Anitoxidant
Mechanism: TW001 is an oral formulation of the free radical scavenger edaravone. Edaravone, marketed under the name Radicut and Radicava, is approved for the treatment of ALS in Japan and South Korea. But this therapy requires frequent intravenous infusions. TW001 is being developed in hopes to provide an option for people with ALS that is easier and more convenient to administer.
U.S. Status for ALS: Phase I

References:
[1] Treeway Announces Positive Data From Two Separate Phase I TW001 Clinical Trials. B3Newswire, 10 Dec 2015. Accessed 21 June 2017.

Last updated June 21st, 2017

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail